NCM · Biotechnology

ALGS (ALGS) Stock

$4.28 -1.04% NCM: ALGS Healthcare

Valuation

MetricValue
Price$4.28
Market Cap$26.45M
P/E Ratio-2.29
P/B Ratio0.64
P/S Ratio7.37
EPS (TTM)$-2.45
52-Week High$13.69
52-Week Low$4.08
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-44.44%
ROA-26.97%
ROCE-162.96%
Gross Margin-4400.00%
Operating Margin-4400.00%
Net Margin-19.20%
Debt/Equity0.14
Current Ratio3.95

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$14.0M$16.0M$4.0M$2.0M
Operating Profit$-128.0M$-98.0M$-88.0M$-89.0M$-88.0M
Net Profit$-128.0M$-96.0M$-88.0M$-131.0M$-24.0M
EPS$-3.22$-2.25$-3.52$-20.94$-2.45
Op Margin-2943.8%-701.7%-567.5%-2259.9%-4024.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$235.0M$147.0M$152.0M$70.0M$89.0M
Total Liabilities$51.0M$43.0M$59.0M$99.0M$35.0M
Cash$187.0M$81.0M$136.0M$37.0M$18.0M
Borrowings$14.0M$13.0M$11.0M$8.0M$5.0M

Latest News

Aligos Therapeutics Completes Enrollment in Phase 2 Study of Potential Chronic Hepatitis B Treatment MT Newswires · Jul 13, 2026 Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection GlobeNewswire · Jul 13, 2026 ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal Stocktwits · Jul 6, 2026 Aligos Gets $25 Million Upfront Payment From Licensing Deal MT Newswires · Jul 6, 2026 Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection GlobeNewswire · Jul 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-116.0M$-79.0M$-79.0M$-81.0M$-83.0M
Investing Cash Flow$2.0M$-27.0M$45.0M$-18.0M$-38.0M
Financing Cash Flow$0$0$71.0M$0$0
Net Cash Flow$-34.0M$-106.0M$54.0M$-99.0M$-19.0M
Free Cash Flow$-117.0M$-80.0M$-79.0M$-81.0M$-83.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-245.82%
Quick Ratio2.56
Interest Coverage—
Return 1Y-31.65%
Return 3Y-77.44%
Return 5Y-98.50%

Ownership

Insiders Held10.76%
Institutions Held55.08%
Institutions Float Held61.72%
Institutional HolderSharesReport Date
Deep Track Capital, Lp444,1102026-03-31
Alyeska Investment Group, L.p.412,0002026-03-31
Sio Capital Management, LLC327,2372026-03-31
Marshall Wace LLP267,1352026-03-31
Bank of America Corporation229,7542026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BRNSBarinthus Biotherapeutics plc $0.67 +4.69% -0.41 — 0.00%
CVM $1.18 +0.00% -0.23 $8.11M 0.00%
FGENFibroGen, Inc. $9.07 -1.63% 0.22 $36.69M 0.00%
INMB $1.73 +6.79% -2.44 $45.99M 0.00%
KZR $7.29 +0.00% -0.96 $53.86M 0.00%

About ALGS

ALGS is led by CEO Lawrence Blatt, publicly traded since 2020.

ALGS stock trades at $4.28 with a market capitalization of $26.45M. The stock is valued at a price-to-earnings (P/E) ratio of -2.29, price-to-book of 0.64, price-to-sales of 7.37. Over the past 52 weeks the stock has ranged between $4.08 and $13.69, and currently trades 68.7% below its 52-week high.

On profitability, ALGS generates a return on equity (ROE) of -44.44%, return on capital employed of -162.96%, an operating margin of -4400.00%, a net profit margin of -19.20%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides